Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma

A. K. Kosmides, R. A. Meyer, J. W. Hickey, K. Aje, K. N. Cheung, J. J. Green, J. P. Schneck

Research output: Contribution to journalArticle

Abstract

Biomimetic materials that target the immune system and generate an anti-tumor responses hold promise in augmenting cancer immunotherapy. These synthetic materials can be engineered and optimized for their biodegradability, physical parameters such as shape and size, and controlled release of immune-modulators. As these new platforms enter the playing field, it is imperative to understand their interaction with existing immunotherapies since single-targeted approaches have limited efficacy. Here, we investigate the synergy between a PLGA-based artificial antigen presenting cell (aAPC) and a checkpoint blockade molecule, anti-PD1 monoclonal antibody (mAb). The combination of antigen-specific aAPC-based activation and anti-PD-1 mAb checkpoint blockade induced the greatest IFN-γ secretion by CD8+ T cells in vitro. Combination treatment also acted synergistically in an in vivo murine melanoma model to result in delayed tumor growth and extended survival, while either treatment alone had no effect. This was shown mechanistically to be due to decreased PD-1 expression and increased antigen-specific proliferation of CD8+ T cells within the tumor microenvironment and spleen. Thus, biomaterial-based therapy can synergize with other immunotherapies and motivates the translation of biomimetic combinatorial treatments.

Original languageEnglish (US)
Pages (from-to)16-26
Number of pages11
JournalBiomaterials
Volume118
DOIs
StatePublished - Feb 1 2017

Fingerprint

Biomimetics
Antigen-Presenting Cells
Melanoma
Tumors
Immunotherapy
Neoplasms
Monoclonal antibodies
T-cells
Antigens
Monoclonal Antibodies
T-Lymphocytes
Biomimetic materials
Immune system
Biodegradability
Biomaterials
Modulators
Chemical activation
Molecules
Biomimetic Materials
Tumor Microenvironment

Keywords

  • Artificial antigen presenting cell
  • CD8+ T-cell
  • Combination therapy
  • Immunotherapy
  • PD-1

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma. / Kosmides, A. K.; Meyer, R. A.; Hickey, J. W.; Aje, K.; Cheung, K. N.; Green, J. J.; Schneck, J. P.

In: Biomaterials, Vol. 118, 01.02.2017, p. 16-26.

Research output: Contribution to journalArticle

Kosmides, A. K.; Meyer, R. A.; Hickey, J. W.; Aje, K.; Cheung, K. N.; Green, J. J.; Schneck, J. P. / Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma.

In: Biomaterials, Vol. 118, 01.02.2017, p. 16-26.

Research output: Contribution to journalArticle

@article{e14a6a5354d849e4afee9389855ffa0d,
title = "Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma",
abstract = "Biomimetic materials that target the immune system and generate an anti-tumor responses hold promise in augmenting cancer immunotherapy. These synthetic materials can be engineered and optimized for their biodegradability, physical parameters such as shape and size, and controlled release of immune-modulators. As these new platforms enter the playing field, it is imperative to understand their interaction with existing immunotherapies since single-targeted approaches have limited efficacy. Here, we investigate the synergy between a PLGA-based artificial antigen presenting cell (aAPC) and a checkpoint blockade molecule, anti-PD1 monoclonal antibody (mAb). The combination of antigen-specific aAPC-based activation and anti-PD-1 mAb checkpoint blockade induced the greatest IFN-γ secretion by CD8+ T cells in vitro. Combination treatment also acted synergistically in an in vivo murine melanoma model to result in delayed tumor growth and extended survival, while either treatment alone had no effect. This was shown mechanistically to be due to decreased PD-1 expression and increased antigen-specific proliferation of CD8+ T cells within the tumor microenvironment and spleen. Thus, biomaterial-based therapy can synergize with other immunotherapies and motivates the translation of biomimetic combinatorial treatments.",
keywords = "Artificial antigen presenting cell, CD8+ T-cell, Combination therapy, Immunotherapy, PD-1",
author = "Kosmides, {A. K.} and Meyer, {R. A.} and Hickey, {J. W.} and K. Aje and Cheung, {K. N.} and Green, {J. J.} and Schneck, {J. P.}",
year = "2017",
month = "2",
doi = "10.1016/j.biomaterials.2016.11.038",
volume = "118",
pages = "16--26",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma

AU - Kosmides,A. K.

AU - Meyer,R. A.

AU - Hickey,J. W.

AU - Aje,K.

AU - Cheung,K. N.

AU - Green,J. J.

AU - Schneck,J. P.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Biomimetic materials that target the immune system and generate an anti-tumor responses hold promise in augmenting cancer immunotherapy. These synthetic materials can be engineered and optimized for their biodegradability, physical parameters such as shape and size, and controlled release of immune-modulators. As these new platforms enter the playing field, it is imperative to understand their interaction with existing immunotherapies since single-targeted approaches have limited efficacy. Here, we investigate the synergy between a PLGA-based artificial antigen presenting cell (aAPC) and a checkpoint blockade molecule, anti-PD1 monoclonal antibody (mAb). The combination of antigen-specific aAPC-based activation and anti-PD-1 mAb checkpoint blockade induced the greatest IFN-γ secretion by CD8+ T cells in vitro. Combination treatment also acted synergistically in an in vivo murine melanoma model to result in delayed tumor growth and extended survival, while either treatment alone had no effect. This was shown mechanistically to be due to decreased PD-1 expression and increased antigen-specific proliferation of CD8+ T cells within the tumor microenvironment and spleen. Thus, biomaterial-based therapy can synergize with other immunotherapies and motivates the translation of biomimetic combinatorial treatments.

AB - Biomimetic materials that target the immune system and generate an anti-tumor responses hold promise in augmenting cancer immunotherapy. These synthetic materials can be engineered and optimized for their biodegradability, physical parameters such as shape and size, and controlled release of immune-modulators. As these new platforms enter the playing field, it is imperative to understand their interaction with existing immunotherapies since single-targeted approaches have limited efficacy. Here, we investigate the synergy between a PLGA-based artificial antigen presenting cell (aAPC) and a checkpoint blockade molecule, anti-PD1 monoclonal antibody (mAb). The combination of antigen-specific aAPC-based activation and anti-PD-1 mAb checkpoint blockade induced the greatest IFN-γ secretion by CD8+ T cells in vitro. Combination treatment also acted synergistically in an in vivo murine melanoma model to result in delayed tumor growth and extended survival, while either treatment alone had no effect. This was shown mechanistically to be due to decreased PD-1 expression and increased antigen-specific proliferation of CD8+ T cells within the tumor microenvironment and spleen. Thus, biomaterial-based therapy can synergize with other immunotherapies and motivates the translation of biomimetic combinatorial treatments.

KW - Artificial antigen presenting cell

KW - CD8+ T-cell

KW - Combination therapy

KW - Immunotherapy

KW - PD-1

UR - http://www.scopus.com/inward/record.url?scp=85002778884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002778884&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2016.11.038

DO - 10.1016/j.biomaterials.2016.11.038

M3 - Article

VL - 118

SP - 16

EP - 26

JO - Biomaterials

T2 - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -